Merck is acquiring Verona Pharma for $10 billion, gaining COPD drug Ohtuvayre as part of its strategy to offset Keytruda’s looming patent loss.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Where Today's News Shapes Tomorrow
